WoundReference improves clinical decisions
 Choose the role that best describes you
Hanft JR, Surprenant MS, et al.
The Journal of foot and ankle surgery : official publication of the American College of Foot an.... Date of publication 2002 Sep 1;volume 41(5):291-9.
1. J Foot Ankle Surg. 2002 Sep-Oct;41(5):291-9. Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis. Hanft JR(1), Surprenant MS. Author information: (1)The Foot & Ankle Institute of South Florida, South Miami 33143, USA. JRHSBRI@aol.com A prospective, multicenter, randomized, controlled 12-week study was undertaken to evaluate the effectiveness of a human fibroblast-derived dermis for treating foot ulcers in the diabetic patient. This report summarizes the findings from one center. Following a 2-week screening period, patients were randomized to either human fibroblast-derived dermis (HFDD) (Dermagraft) plus saline-moistened gauze or to the control group (CT) of saline-moistened gauze alone. Effectiveness end points were: 1) wound closure by week 12, 2) time to wound closure, and 3) percent wound closure by week 12. Safety was assessed by review of adverse events and laboratory findings. Patients randomized to HFDD received an application at day 0 and up to seven additional treatments. All patients in each group received shoes with custom-molded inserts and were seen weekly. The study population was comprised of 28 patients (14 HFDD/14 CT) with chronic ulcers (>6 weeks' duration at time of screening). By week 12, significantly more chronic ulcers healed in the HFDD group than in the CT group (71.4% versus 14.3%, p = .003). Healed HFDD patients achieved wound closure significantly faster than CT patients (p = .004). Patients treated with HFDD showed a statistically significant higher percent of wound closure by week 12 than did CT patients (p = .002). The percent of patients who experienced an infection involving their study wound was less in the HFDD group than in the CT group. It was concluded that HFDD is a safe and effective treatment for chronic foot ulcers in diabetic patients. PMID: 12400712 [Indexed for MEDLINE]
Appears in following Topics:
Cellular and/or Tissue Based Products